Full video transcriptClick to expand
Auto-generated transcript of @greta.div's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I use MT1 over MT2 and I wanted to explain why and which peptide is best for what situation you're in.
- 0:10MT1 is also called a fam-alanotide and it only affects the MC1 receptors, which are the receptors responsible for producing melanin in the skin.
- 0:21And it's also prescribed medically for a condition called earthythropietic protoporothirea, which is basically a long way of saying that you're allergic to the sun or you're really pale.
- 0:36In contrast, MT2 hits other receptors besides just the MC1 receptors. It also hits the receptors in your brain that are responsible for your libido and your appetite.
- 0:49And it also has more side effects, so it can cause headaches and blood pressure problems.
- 0:55It could be wrong, but I believe that MT2 is going through trials to treat sexual dysfunction.
- 1:01And MT2 also has the side effects of decreasing, or sorry, decreasing your appetite.
- 1:07MT2 also works a lot quicker and a lot stronger and is a bit more reactive to sunlight from what I've seen.
- 1:14So MT2 is better if you're going on a vacation, right?
- 1:18And you just want something to help you tan and not burn while you're on vacation.
- 1:22But you're going to have side effects from it, okay? Like long term use, MT1, I feel like is a lot safer and it doesn't.
- 1:29I just don't want to mess with things involving my reproductive system.
- 1:34I don't know, in my head MT2 is like bi-a-gra or something and I'm like, I'm a girl.
- 1:40Like I don't think I shouldn't be thinking that.
@greta.div's MT2 tanning claims need some serious context
Quick answer
Afamelanotide (MT1) is FDA-approved under the brand name Scenesse for erythropoietic protoporphyria, a rare photosensitivity disorder, and works through selective MC1 receptor agonism. Melanotan II is a non-selective melanocortin agonist with activity at MC1, MC3, MC4, and MC5 receptors, producing tanning alongside systemic effects including appetite suppression and sexual arousal mediated primarily through MC4 receptor activation. Neither compound is approved for cosmetic tanning, and compounded or gray-market versions carry unverified purity and dosing risks that fall outside any established safety profile.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @greta.div's MT2 tanning claims need some serious context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
VYLEESI (bremelanotide injection) FDA Prescribing Information
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval is limited to that indication.
FDA
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Pivotal RECONNECT studies: two double-blind placebo-controlled Phase 3 trials (1,267 women) showing improved sexual desire and reduced distress versus placebo.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@greta.div's MT2 tanning claims need some serious context should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@greta.div's MT2 tanning claims need some serious context" from Greta Devereux. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Afamelanotide (MT1) is FDA-approved under the brand name Scenesse for erythropoietic protoporphyria, a rare photosensitivity disorder, and works through selective MC1 receptor agonism.
The reason this review is not generic is the source wording and the canonical claim label "peptides mt2 tanning tanningproducts selftanning." In this clip, the useful excerpt is: "I use MT1 over MT2 and I wanted to explain why and which peptide is best for what situation you're in." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against SCENESSE (afamelanotide implant) FDA Prescribing Information (2019), Afamelanotide for Erythropoietic Protoporphyria (2015), and Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (2012), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Afamelanotide (MT1) is FDA-approved under the brand name Scenesse for erythropoietic protoporphyria, a rare photosensitivity disorder, and works through selective MC1 receptor agonism.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Afamelanotide (MT1) is FDA-approved under the brand name Scenesse for erythropoietic protoporphyria, a rare photosensitivity disorder, and works through selective MC1 receptor agonism. Melanotan II is a non-selective melanocortin agonist with activity at MC1, MC3, MC4, and MC5 receptors, producing tanning alongside systemic effects including appetite suppression and sexual arousal mediated primarily through MC4 receptor activation. Neither compound is approved for cosmetic tanning, and compounded or gray-market versions carry unverified purity and dosing risks that fall outside any established safety profile.
- Afamelanotide has FDA approval under the brand name Scenesse, but only for erythropoietic protoporphyria, not cosmetic tanning. No version of MT1 or MT2 is approved for tanning anywhere.
- Melanotan II activates at least four melanocortin receptor subtypes (MC1, MC3, MC4, MC5), and the systemic effects she describes, including appetite suppression and libido changes, are real and documented in peer-reviewed literature.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Afamelanotide has FDA approval under the brand name Scenesse, but only for erythropoietic protoporphyria, not cosmetic tanning. No version of MT1 or MT2 is approved for tanning anywhere.
- Melanotan II activates at least four melanocortin receptor subtypes (MC1, MC3, MC4, MC5), and the systemic effects she describes, including appetite suppression and libido changes, are real and documented in peer-reviewed literature.
- The MT2 analog bremelanotide (PT-141) received FDA approval in 2019 as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, which directly contradicts the idea that MT2-type compounds are irrelevant or wrong for women.
- Documented MT2 side effects in clinical settings include transient hypotension, nausea, facial flushing, and spontaneous erections in men (Dorr et al., 1996, Journal of Clinical Oncology). Blood pressure effects are not trivial.
- Gray-market peptide products labeled as MT1 or MT2 have no verified purity, sterility, or dosing accuracy. What is in the vial may not match the label.
- MC4 receptor activation drives both appetite suppression and sexual arousal effects of MT2. These are not separate mechanisms but related expressions of the same receptor target studied extensively in human obesity research (Farooqi et al., 2003, Science).
- The creator's core advice that MT1 carries a cleaner side effect profile than MT2 for cosmetic purposes is consistent with the receptor pharmacology, but neither compound is a safe DIY tanning tool outside medical supervision.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @greta.div actually say?
The creator argues that MT1 (afamelanotide) is the safer long-term choice for tanning because it only activates MC1 receptors, while MT2 (melanotan II) also hits brain receptors tied to libido and appetite. Her bottom line: use MT2 for a quick vacation tan, but expect side effects, and stick to MT1 if you want something less disruptive to your hormonal system.
She also notes that MT1 is medically prescribed, mentions MT2 may be in trials for sexual dysfunction, and flags specific MT2 side effects including headaches, blood pressure changes, and appetite suppression. That is a reasonably structured comparison for a TikTok video, and she gets more right than wrong. But there are real errors worth correcting before you inject anything.
Does the science back this up?
Partially, yes. The receptor selectivity argument is the strongest part of her case and it holds up. Afamelanotide is a selective MC1 agonist, and that selectivity is well-documented in the literature. Melanotan II is a non-selective melanocortin agonist that activates MC1, MC3, MC4, and MC5 receptors.
MC4 receptor activation is the relevant one here. MC4 is expressed in the hypothalamus and is linked to both sexual arousal and appetite regulation. This is why melanotan II produces spontaneous erections in male subjects and appetite suppression, effects documented in early Dorr et al. (1996, Journal of Clinical Oncology) work on afamelanotide and subsequent MT2 human trials. Wessells et al. (2000, Journal of Urology) confirmed intranasal MT2 produced erections in men with psychogenic erectile dysfunction, which is likely the trial she is half-remembering. She is correct that those receptor-mediated side effects are real and distinguishable from MT1's profile.
What did they get wrong (or right)?
The disease name needs a correction. She calls it "earthythropietic protoporothirea," which is a phonetic guess at erythropoietic protoporphyria (EPP). That is forgivable on a TikTok. The condition itself is accurately described as a severe photosensitivity disorder, not simply being "allergic to the sun or really pale." EPP involves a specific enzyme deficiency causing painful phototoxic reactions. That distinction matters clinically.
Her framing of MT2 as essentially "like Viagra" for women is where she goes off track. MC4 activation in women does affect arousal pathways, but the mechanism is different from PDE5 inhibition, which is how sildenafil works. Bremelanotide (PT-141), an MT2 analog, was FDA-approved in 2019 under the name Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women. So if anything, MT2's sexual effects are arguably more relevant to women than she realizes, not less. Dismissing it with "I'm a girl" undersells the pharmacology.
- Receptor selectivity claim: accurate
- EPP description: mostly accurate but oversimplified
- MT2 trials for sexual dysfunction: accurate, though the drug is already approved as bremelanotide
- Side effect profile comparison: mostly accurate
- "MT2 is like Viagra" framing: misleading
What should you actually know?
Neither peptide is approved for cosmetic tanning in the US, UK, or EU. Afamelanotide is FDA-approved only for EPP under the brand name Scenesse. Melanotan II has no regulatory approval anywhere for any indication. Bremelanotide (the MT2 analog) is FDA-approved for HSDD but is not the same compound being sold as "MT2" in gray-market peptide supply chains.
Compounded or research-grade versions of these peptides carry significant unknowns around purity, dosing accuracy, and sterility. Blood pressure changes from MT2 are not minor. Clinically documented effects include nausea, facial flushing, and transient hypotension (Dorr et al., 1996). The appetite suppression she mentions is real and mediated through MC4, the same receptor implicated in MC4R mutation studies on human obesity (Farooqi et al., 2003, Science).
If you are considering either peptide, this is a conversation for a licensed provider who can assess your full health picture, not a TikTok comment section.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Greta Devereux · TikTok creator
424.4K views on this video
#mt2 #tanning #tanningproducts #selftanning
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about afamelanotide has fda approval under the brand name scenesse,?
Afamelanotide has FDA approval under the brand name Scenesse, but only for erythropoietic protoporphyria, not cosmetic tanning. No version of MT1 or MT2 is approved for tanning anywhere.
What does the video say about melanotan ii activates at least four melanocortin receptor subtypes (mc1,?
Melanotan II activates at least four melanocortin receptor subtypes (MC1, MC3, MC4, MC5), and the systemic effects she describes, including appetite suppression and libido changes, are real and documented in peer-reviewed literature.
What does the video say about the mt2 analog bremelanotide (pt-141) received fda approval in 2019?
The MT2 analog bremelanotide (PT-141) received FDA approval in 2019 as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, which directly contradicts the idea that MT2-type compounds are irrelevant or wrong for women.
Documented MT2 side effects in clinical settings include transient hypotension, nausea, facial flushing, and spontaneous erections in men (Dorr et al., 1996, Journal of Clinical Oncology). Blood pressure effects are not trivial?
Documented MT2 side effects in clinical settings include transient hypotension, nausea, facial flushing, and spontaneous erections in men (Dorr et al., 1996, Journal of Clinical Oncology). Blood pressure effects are not trivial.
What does the video say about gray-market peptide products labeled as mt1?
Gray-market peptide products labeled as MT1 or MT2 have no verified purity, sterility, or dosing accuracy. What is in the vial may not match the label.
What does the video say about mc4 receptor activation drives both appetite suppression?
MC4 receptor activation drives both appetite suppression and sexual arousal effects of MT2. These are not separate mechanisms but related expressions of the same receptor target studied extensively in human obesity research (Farooqi et al., 2003, Science).
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Greta Devereux, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.